{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T05:55:31Z","timestamp":1777874131516,"version":"3.51.4"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.vaccine.2026.128573","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T15:22:24Z","timestamp":1775834544000},"page":"128573","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Unlocking Africa's vaccine Independence: The critical role of technology transfer and intellectual property"],"prefix":"10.1016","volume":"81","author":[{"given":"Pierre","family":"Gashema","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick Gad","family":"Iradukunda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean Claude","family":"Rudacogora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel Edwar","family":"Siddig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hugor","family":"Shema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radjabu","family":"Bigirimana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"de Dieu Harelimana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mina","family":"Louis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claude Mambo","family":"Muvunyi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.128573_bb0015","series-title":"Africa CDC Warns: Millions of African Children Still Lack Access to Life-Saving Vaccines","year":"2025"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128573_bb0020","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/hast.1250","article-title":"Out of Africa: a solidarity-based approach to vaccine allocation","volume":"51","author":"Jecker","year":"2021","journal-title":"Hast Cent Rep"},{"key":"10.1016\/j.vaccine.2026.128573_bb0025","doi-asserted-by":"crossref","unstructured":"C. Mwila et al., \u201cOperationalizing African self-reliance in vaccine manufacturing,\u201d Glob Health Action, vol. 18, no. 1, p. 2560209, doi:https:\/\/doi.org\/10.1080\/16549716.2025.2560209.","DOI":"10.1080\/16549716.2025.2560209"},{"key":"10.1016\/j.vaccine.2026.128573_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.126829","article-title":"Advancing local manufacturing capacities for vaccines within Africa \u2013 opportunities, priorities and challenges","volume":"50","author":"Doua","year":"2025","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128573_bb0035","article-title":"Revolutionizing immunization: a comprehensive review of mRNA vaccine technology and applications","volume":"22","author":"Leong","year":"2025","journal-title":"Virol J"},{"issue":"16","key":"10.1016\/j.vaccine.2026.128573_bb0040","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1016\/j.vaccine.2021.03.038","article-title":"mRNA vaccines manufacturing: challenges and bottlenecks","volume":"39","author":"Rosa","year":"2021","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128573_bb0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgph.0002098","article-title":"Expanding global vaccine manufacturing capacity: strategic prioritization in small countries","volume":"3","author":"Mukherjee","year":"2023","journal-title":"PLoS Glob Public Health"},{"key":"10.1016\/j.vaccine.2026.128573_bb0050","series-title":"Intellectual Property (IP) and Technology Transfer for COVID-19 Vaccines: Assessment of the Record","year":"2026"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128573_bb0055","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1057\/s42214-021-00124-7","article-title":"The world has a unique opportunity: accelerating technology transfer and vaccine production through partnerships","volume":"5","author":"Fu","year":"2022","journal-title":"J Int Bus Policy"},{"issue":"12","key":"10.1016\/j.vaccine.2026.128573_bb0060","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines9121490","article-title":"Vaccine Technologies and Platforms for Infectious Diseases: current progress, challenges, and opportunities","volume":"9","author":"Ghattas","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2026.128573_bb0065","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2025.1547025","article-title":"mRNA vaccine platforms: linking infectious disease prevention and cancer immunotherapy","volume":"13","author":"Haghmorad","year":"2025","journal-title":"Front Bioeng Biotechnol"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128573_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.respol.2023.104937","article-title":"Technology transfer challenges in asymmetric alliances between high-technology and low-technology firms","volume":"53","author":"Simms","year":"2024","journal-title":"Res Policy"},{"key":"10.1016\/j.vaccine.2026.128573_bb0075","series-title":"Globally Resilient Supply Chains for Seasonal and Pandemic Influenza Vaccines","article-title":"Critical Components for Vaccine Manufacturing","author":"N. A. of Medicine","year":"2021"},{"key":"10.1016\/j.vaccine.2026.128573_bb0080","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2022.1021905","article-title":"Current GMP standards for the production of vaccines and antibodies: an overview","volume":"10","author":"Covarrubias","year":"2022","journal-title":"Front Public Health"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128573_bb0090","doi-asserted-by":"crossref","first-page":"646","DOI":"10.3390\/vaccines13060646","article-title":"Strengthening National Regulatory Authorities in Africa: a critical step towards enhancing local manufacturing of vaccines and health products","volume":"13","author":"Duga","year":"2025","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2026.128573_bb0100","doi-asserted-by":"crossref","DOI":"10.1093\/jiplp\/jpab129","article-title":"Compulsory licensing of trade secrets: ensuring access to COVID-19 vaccines via involuntary technology transfer","author":"Gurgula","year":"2021","journal-title":"Journal of Intellectual Property Law & Practice"},{"issue":"9","key":"10.1016\/j.vaccine.2026.128573_bb0105","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2023-012964","article-title":"Negotiating public-health intellectual property licensing agreements to increase access to health technologies: an insider\u2019s story","volume":"8","author":"Gore","year":"2023","journal-title":"BMJ Glob Health"},{"key":"10.1016\/j.vaccine.2026.128573_bb0110","series-title":"Africa\u2019s Progress Towards Sustainable Local Manufacturing Health Products","year":"2025"},{"key":"10.1016\/j.vaccine.2026.128573_bb0115","author":"L. H. S. P. at E. P. H. is at the forefront of chronicling the dynamic world of biotech startups W. a background in molecular biology, B. Engineering, H. B. a U. P. to the Scientific, and E. A. of the B. Industry"},{"key":"10.1016\/j.vaccine.2026.128573_bb0120","series-title":"A Primer on Technology Transfer in the Field of Biotechnology","author":"World Intellectual Property Organization","year":"2025"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128573_bb0135","doi-asserted-by":"crossref","DOI":"10.1093\/jlb\/lsaf020","article-title":"Ensuring vaccine access through local production: the need for a harmonized and sustainable approach","volume":"12","author":"Tsega","year":"2025","journal-title":"J Law Biosci"},{"issue":"11","key":"10.1016\/j.vaccine.2026.128573_bb0140","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1586\/14760584.2015.1083430","article-title":"Current status and future prospects of Yellow Fever vaccines","volume":"14","author":"Beck","year":"2015","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2026.128573_bb0155","article-title":"Compulsory licensing of pharmaceuticals during public health crisis: a TRIPS framework analysis","volume":"13","author":"Li","year":"2025","journal-title":"Front Public Health"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128573_bb0160","first-page":"159","article-title":"Improving access to COVID-19 vaccines: an analysis of TRIPS waiver discourse among WTO members, civil society organizations, and pharmaceutical industry stakeholders","volume":"24","author":"Kohler","year":"2022","journal-title":"Health Hum Rights"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128573_bb0165","doi-asserted-by":"crossref","DOI":"10.1002\/puh2.158","article-title":"Good manufacturing practice in low- and middle-income countries: challenges and solutions for compliance","volume":"3","author":"Chejor","year":"2024","journal-title":"Public Health Challenges"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128573_bb0175","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202216287","article-title":"Strengthening vaccines and medicines manufacturing capabilities in Africa: challenges and perspectives","volume":"14","author":"Saied","year":"2022","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.vaccine.2026.128573_bb0185","series-title":"Global Partners Invest $45 Million to Boost African Vaccine Production","author":"A. D. Bank","year":"2026"},{"key":"10.1016\/j.vaccine.2026.128573_bb0195","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12961-018-0303-3","article-title":"An evaluation of South Africa\u2019s public\u2013private partnership for the localisation of vaccine research, manufacture and distribution","volume":"16","author":"Walwyn","year":"2018","journal-title":"Health Res Policy Syst"},{"key":"10.1016\/j.vaccine.2026.128573_bb0200","series-title":"South Africa: EIB to support increased vaccine production by Biovac","year":"2026"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128573_bb0210","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s10479-020-03912-1","article-title":"Supply chain disruptions and resilience: a major review and future research agenda","volume":"319","author":"Katsaliaki","year":"2022","journal-title":"Ann Oper Res"},{"key":"10.1016\/j.vaccine.2026.128573_bb0215","doi-asserted-by":"crossref","unstructured":"G. Kumraj et al., \u201cCapacity building for vaccine manufacturing across developing countries: the way forward,\u201d Hum Vaccin Immunother, vol. 18, no. 1, p. 2020529, doi:https:\/\/doi.org\/10.1080\/21645515.2021.2020529.","DOI":"10.1080\/21645515.2021.2020529"},{"issue":"50","key":"10.1016\/j.vaccine.2026.128573_bb0220","doi-asserted-by":"crossref","first-page":"7288","DOI":"10.1016\/j.vaccine.2022.10.044","article-title":"Sustainable vaccine manufacturing in low- and middle-income countries","volume":"40","author":"Hayman","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128573_bb0225","series-title":"Vaccine R&D and Vaccine Manufacturing Competency Frameworks","year":"2025"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128573_bb0230","doi-asserted-by":"crossref","DOI":"10.1002\/puh2.172","article-title":"A new era for African health systems: market shaping and the African Continental Free Trade Area (AfCFTA)","volume":"3","author":"Kamara","year":"2024","journal-title":"Public Health Challenges"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26003816?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26003816?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T19:07:20Z","timestamp":1777576040000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26003816"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":34,"alternative-id":["S0264410X26003816"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128573","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unlocking Africa's vaccine Independence: The critical role of technology transfer and intellectual property","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128573","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"128573"}}